In this report, the authors present three cases of advanced mutant RET medullary thyroid cancer or lung adenocarcinoma, where the tumor responses to selpercatinib were measured using 2-deoxy-2-(18F)fluoro-D-glucose (18FDG)-PET/CT. This evidence concerns the gene RET and medullary thyroid gland carcinoma.